Novartis has kept up with its Figures for the year 2018 of the word and grew in the mid single-digit percentage range. The Pharma has benefited the group, particularly to the good development of the growth drivers.
The shareholders will be involved with a 5 cents to 2.85 francs increased dividend on the success. For 2019, the group has set itself a further growth to the target. The net sales for 2018, Novartis 2018 is estimated at 51.9 billion US dollars – an increase of 6 percent compared to the same period last year, as Novartis announced on Wednesday.
for This purpose, the pharmaceutical division contributed Innovative Medicines with 34.9 billion (+8%) the lion’s share. The good performance of the group due primarily to the sales of Cosentyx, and other products that achieved the blockbuster status. Blockbusters are drugs that flush more than 1 billion turnover in the Fund. The other two divisions, Sandoz and Alcon developed, however, was uneven. In the eyes division Alcon, revenues increased by 6 percent to 7.1 billion dollars.
Less sales generic
accept The generics division, Sandoz, had a turnover decline of 2 percent to 9.9 billion dollars. Here, the price pressure on the American made market will continue to have a negative impact, it was said in the message.
The core operating profit for the financial year rose by 8 per cent to 13.8 billion dollars. The increase in Novartis leads back mainly to the increased sales and higher gross margins.
the bottom line is that the cash registers were ringing however. The net profit is not high jumped due to the sale of the investment in the joint venture with the pharmaceutical company GSK in the area of prescription drugs to 12.6 billion dollars. The are 64 percent more than a year ago.
expectations
With the Numbers, the group has met the average estimates from Reuters surveyed analysts.
The Outlook for the fiscal year 2019 Novartis for the group sales in the mid-single-digit percent range in view. The core operating income is expected to rise in the mid-to-high percentage.
The planned spin-off of the eye division Alcon will be held in the first half of the year. Thus, the group confirmed its previous schedule.
Novartis chief Narasimhan conceded 6.68 million
The new Novartis chief Vasant Narasimhan, in his first year at the helm of the Pharma group’s 6.68 million Swiss francs earned. For comparison, His predecessor, Joseph Jimenez had been paid in his last year in office in 2017, with 11.3 million Swiss francs.
The handover between the two managers was on 1. February 2018 completed. To this time been announced, that Narasimhan would start with a lower target compensation, as it is for the first time as a CEO in a company. As the target remuneration at the time of 8.9 million Swiss francs was called.
Board of Directors receive 8.2 million
The entire business line in 2018, a realized total compensation of 66.3 million Swiss francs was awarded to 47.5 million in the previous year. It also includes the compensation of the four managers resigned during the year are included.
Chairman of the Board Jörg Reinhardt will be paid for the financial year 2018, as in the previous year, with 3.8 million Swiss francs. To all the members of the Board, for a total of 8.2 million Swiss francs were paid to 8.4 million in the previous year. (ij/sda)
Created: 30.01.2019, 07:11 PM
